Analyst Research

Report Title Price
Provider: Stock Traders Daily
$20.00
Provider: Reuters Investment Profile
$20.00
Provider: Thomson Reuters Stock Report
$25.00
Provider: New Constructs, LLC
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Halozyme Therapeutics Inc announces roche marketing authorization for MabThera SC for patients with common forms of non-Hodgkin Lymphoma In European Union


Friday, 28 Mar 2014 08:00am EDT 

Halozyme Therapeutics Inc:European Commission has approved Roche's new subcutaneous (SC) formulation of MabThera (rituximab) for treatment of patients with follicular lymphoma and diffuse large B-cell lymphoma. 

Company Quote

8.52
0.1 +1.19%
21 Nov 2014